Veracyte Retained Earnings from 2010 to 2025

VCYT Stock

USD 31.23 2.46 7.30%

Veracyte Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Veracyte retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2012-12-31

Previous Quarter

-449.1 M

Current Value

-444 M

Quarterly Volatility

128.7 M

Yuan Drop

Covid

Check Veracyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Veracyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 24.6 M, Interest Expense of 1.9 K or Selling General Administrative of 187.2 M, as well as many indicators such as Price To Sales Ratio of 13.72, Dividend Yield of 0.0 or PTB Ratio of 2.48. Veracyte financial statements analysis is a perfect complement when working with Veracyte Valuation or Volatility modules.

Check out the analysis of Veracyte Correlation against competitors.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Latest Veracyte's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Veracyte over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Veracyte's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Veracyte's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (443.98 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Veracyte Retained Earnings Regression Statistics

	Arithmetic Mean	(224,281,991)
	Coefficient Of Variation	(71.84)
	Mean Deviation	131,608,866
	Median	(211,087,000)
	Standard Deviation	161,121,717
	Sample Variance	25960.2T
	Range	524.6M
	R-Value	(0.96)
	Mean Square Error	2253.5T
	R-Squared	0.92
	Slope	(32,442,464)
	Total Sum of Squares	389403.1T

Veracyte Retained Earnings History

	2025	-421.8 M
	2024	-444 M
	2023	-468.1 M
	2022	-393.7 M
	2021	-357.2 M
	2020	-281.6 M
	2019	-246.7 M

Other Fundumenentals of Veracyte

Retained Earnings Total Equity

Veracyte Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		1.0	-0.68	-0.89	0.79	0.98	0.93	0.87	0.82	0.97	0.74	0.9	-0.49	0.98	-0.49	1.0	0.56	0.84	-0.43	-0.08	0.84	0.75	0.98	0.81
Total Stockholder Equity	1.0		-0.69	-0.88	0.79	0.98	0.92	0.87	0.82	0.97	0.73	0.9	-0.5	0.98	-0.5	1.0	0.56	0.85	-0.44	-0.09	0.84	0.75	0.98	0.82
Net Debt	-0.68	-0.69		0.7	-0.45	-0.68	-0.57	-0.93	-0.77	-0.58	-0.42	-0.85	0.52	-0.53	0.52	-0.69	-0.7	-0.59	0.49	0.28	-0.62	-0.97	-0.76	-0.41
Retained Earnings	-0.89	-0.88	0.7		-0.69	-0.94	-0.87	-0.85	-0.9	-0.91	-0.62	-0.84	0.24	-0.83	0.24	-0.9	-0.7	-0.76	0.27	-0.04	-0.79	-0.78	-0.89	-0.65
Accounts Payable	0.79	0.79	-0.45	-0.69		0.75	0.67	0.55	0.76	0.79	0.33	0.58	-0.4	0.82	-0.4	0.76	0.3	0.81	-0.32	-0.03	0.57	0.45	0.78	0.82
Net Receivables	0.98	0.98	-0.68	-0.94	0.75		0.94	0.88	0.88	0.97	0.73	0.89	-0.37	0.95	-0.37	0.98	0.64	0.84	-0.36	-0.01	0.84	0.76	0.96	0.78
Total Liab	0.93	0.92	-0.57	-0.87	0.67	0.94		0.83	0.79	0.96	0.84	0.81	-0.25	0.9	-0.25	0.94	0.55	0.71	-0.25	0.09	0.8	0.66	0.88	0.69
Total Current Assets	0.87	0.87	-0.93	-0.85	0.55	0.88	0.83		0.84	0.81	0.7	0.95	-0.47	0.75	-0.47	0.88	0.7	0.68	-0.45	-0.16	0.81	0.95	0.89	0.54
Common Stock	0.82	0.82	-0.77	-0.9	0.76	0.88	0.79	0.84		0.83	0.47	0.77	-0.25	0.74	-0.25	0.82	0.77	0.82	-0.28	0.01	0.66	0.8	0.86	0.67
Property Plant Equipment	0.97	0.97	-0.58	-0.91	0.79	0.97	0.96	0.81	0.83		0.74	0.83	-0.33	0.97	-0.33	0.98	0.57	0.8	-0.29	0.06	0.82	0.65	0.94	0.79
Short Term Investments	0.74	0.73	-0.42	-0.62	0.33	0.73	0.84	0.7	0.47	0.74		0.76	-0.32	0.71	-0.32	0.76	0.31	0.42	-0.31	-0.05	0.81	0.55	0.68	0.36
Net Tangible Assets	0.9	0.9	-0.85	-0.84	0.58	0.89	0.81	0.95	0.77	0.83	0.76		-0.55	0.82	-0.55	0.91	0.57	0.66	-0.5	-0.21	0.93	0.9	0.92	0.52
Long Term Debt	-0.49	-0.5	0.52	0.24	-0.4	-0.37	-0.25	-0.47	-0.25	-0.33	-0.32	-0.55		-0.46	1.0	-0.47	-0.14	-0.46	0.79	0.67	-0.43	-0.51	-0.55	-0.39
Good Will	0.98	0.98	-0.53	-0.83	0.82	0.95	0.9	0.75	0.74	0.97	0.71	0.82	-0.46		-0.46	0.97	0.44	0.81	-0.4	-0.04	0.82	0.61	0.94	0.84
Long Term Debt Total	-0.49	-0.5	0.52	0.24	-0.4	-0.37	-0.25	-0.47	-0.25	-0.33	-0.32	-0.55	1.0	-0.46		-0.47	-0.14	-0.46	0.79	0.67	-0.43	-0.51	-0.55	-0.39
Capital Surpluse	1.0	1.0	-0.69	-0.9	0.76	0.98	0.94	0.88	0.82	0.98	0.76	0.91	-0.47	0.97	-0.47		0.57	0.82	-0.43	-0.08	0.86	0.76	0.98	0.79
Deferred Long Term Liab	0.56	0.56	-0.7	-0.7	0.3	0.64	0.55	0.7	0.77	0.57	0.31	0.57	-0.14	0.44	-0.14	0.57		0.63	-0.12	0.09	0.37	0.72	0.61	0.46
Intangible Assets	0.84	0.85	-0.59	-0.76	0.81	0.84	0.71	0.68	0.82	0.8	0.42	0.66	-0.46	0.81	-0.46	0.82	0.63		-0.39	-0.06	0.52	0.63	0.86	0.92
Short Long Term Debt	-0.43	-0.44	0.49	0.27	-0.32	-0.36	-0.25	-0.45	-0.28	-0.29	-0.31	-0.5	0.79	-0.4	0.79	-0.43	-0.12	-0.39		0.93	-0.39	-0.49	-0.47	-0.34
Short Term Debt	-0.08	-0.09	0.28	-0.04	-0.03	-0.01	0.09	-0.16	0.01	0.06	-0.05	-0.21	0.67	-0.04	0.67	-0.08	0.09	-0.06	0.93		-0.12	-0.26	-0.13	-0.01
Net Invested Capital	0.84	0.84	-0.62	-0.79	0.57	0.84	0.8	0.81	0.66	0.82	0.81	0.93	-0.43	0.82	-0.43	0.86	0.37	0.52	-0.39	-0.12		0.7	0.84	0.4
Net Working Capital	0.75	0.75	-0.97	-0.78	0.45	0.76	0.66	0.95	0.8	0.65	0.55	0.9	-0.51	0.61	-0.51	0.76	0.72	0.63	-0.49	-0.26	0.7		0.82	0.44
Capital Stock	0.98	0.98	-0.76	-0.89	0.78	0.96	0.88	0.89	0.86	0.94	0.68	0.92	-0.55	0.94	-0.55	0.98	0.61	0.86	-0.47	-0.13	0.84	0.82		0.79
Current Deferred Revenue	0.81	0.82	-0.41	-0.65	0.82	0.78	0.69	0.54	0.67	0.79	0.36	0.52	-0.39	0.84	-0.39	0.79	0.46	0.92	-0.34	-0.01	0.4	0.44	0.79

Click cells to compare fundamentals

About Veracyte Financial Statements

Veracyte shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Veracyte investors may analyze each financial statement separately, they are all interrelated. The changes in Veracyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on Veracyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-444 M	-421.8 M
Retained Earnings Total Equity	-354.3 M	-372.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC